title: Systemic and targeted therapy for biliary tract tumors and primary liver tumors.
abstract: Tumors of the biliary tract and hepatocellular carcinoma (HCC) are complex tumors with heterogeneous carcinogenic mechanisms. Patients with hepatobiliary cancer have advances disease and need systematic therapy to palliate symptoms and extend survival. Development of effective systematic therapy is a significant unmet medical need. It is hoped that current and future clinical trials will identify additional effective systemic agents, combination systemic therapies, and combined modality options. The HCC community needs validated biomarkers to help identify the patients who will benefit most from emerging treatment options.
authors.affiliation: Hollings Cancer Center, College of Medicine, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA. Electronic address: thomasmb@musc.edu.
authors.forename: Melanie Byrne
authors.initials: MB
authors.lastname: Thomas
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001661:Biliary Tract Neoplasms / Q000188:drug therapy*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D016503:Drug Delivery Systems / Q000379:methods; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*
keywords: Bile duct cancer cholangiocarcinoma; Chemotherapy; Hepatocellular carcinoma; Systemic therapy; Targeted therapies